AVITA Medical, Inc.

NASDAQ•RCEL

CEO: Mr. James M. Corbett

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2012-05-14

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Contact Information

28159 Avenue Stanford, Suite 220, Valencia, CA, 91355, United States

661-367-9170

www.avitamedical.com

Market Cap

$119.25M

P/E (TTM)

-3.0

26.9

Dividend Yield

52W High

$10.29

52W Low

$3.22

52W Range

22%

Rank55Top 80.0%

2.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$17.62M+0.00%

4-Quarter Trend

EPS

-$0.38+0.00%

4-Quarter Trend

FCF

-$3.73M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Growth 11% Total revenues reached $71.6M USD in 2025, growing 11% driven by deeper penetration and new product launches.

Operating Loss Reduced 25% Operating loss narrowed by 25% to $42.5M USD in 2025; total operating expenses decreased 9% to $101.4M USD.

Platform Expansion Complete Launched Cohealyx in April 2025; RECELL GO mini commercial rollout began Q1 2025, expanding acute wound care portfolio.

Favorable Reimbursement Secured Received NTAP approval in October 2025 for full-thickness defects, providing up to $4,875 incremental reimbursement per case.

Risk Factors

Continued Net Losses Incurred $48.6M net loss in 2025, following $61.8M loss in 2024; profitability remains uncertain for foreseeable future.

Going Concern Doubt Management determined substantial doubt regarding ability to continue as going concern over next twelve months due to recurring losses.

Debt Covenants Restrictive Subject to restrictive covenants under new $60M Perceptive Credit Agreement; failure to meet net revenue tests risks default.

Supply Chain Single-Sourced Certain key components are single-sourced, creating material risk of disruption, delays, or unfavorable cost increases impacting margins.

Outlook

Drive Portfolio Adoption Strategy centers on increasing RECELL penetration in U.S. burn centers while expanding Cohealyx and PermeaDerm adoption.

International Expansion Focus Pursuing distributor-led commercialization in Europe following September 2025 CE Mark approval for RECELL GO.

Achieve Profitability Goals Objectives include driving commercial revenue growth, improving operating leverage, and generating positive cash flow long-term.

Advance Clinical Evidence Continuing post-market studies for Cohealyx and PermeaDerm to generate health economic evidence supporting broader adoption.

Peer Comparison

Revenue (TTM)

QIPT

$315.49M

+31.9%

XTNT

$133.08M

+16.9%

ANIK

$112.82M

+3.8%

Gross Margin (Latest Quarter)

SGHT

87.3%

+2.5pp

OVID

87.1%

-12.9pp

RCEL

81.2%

-2.4pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ANIK	$207.09M	-18.8	-7.4%	12.7%
SGHT	$199.82M	-5.1	-55.7%	35.0%
RPID	$194.13M	-4.4	-73.9%	28.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-1.6%

Flat Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data